Welcome to this special episode of the
NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this special edition of
Mind Moments, Patricia Pozo-Rosich, MD, PhD, head of the neurology department at Vall d’Hebron University Hospital, discussed the recent FDA approval of fremanezumab (Ajovy) for pediatric migraine prevention. As a study author on the pivotal phase 3 SPACE trial (NCT03539393), Dr. Pozo-Rosich reflected on the significance of having a proven therapeutic option in a population where placebo responses and lack of evidence have long complicated care. She provided insights on how the trial was designed and the challenges of running pediatric studies, particularly in adolescents. Additionally, she highlighted broader implications for migraine research, including efforts to reduce placebo effects, the role of CGRP pathway inhibition in younger patients, and the future promise of emerging targets such as PACAP antagonists and new toxin formulations.
Episode Breakdown:
1:10 – Initial reaction to fremanezumab approval and significant for pediatric migraine care
6:05 – Major clinical insights and takeaways from phase 3 SPACE trial
10:20 – Challenges in pediatric migraine trials and addressing high placebo responses
15:10 – Future directions in migraine therapy, including PACAP-targeting drugs and novel approaches
Thanks for listening to the
NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit
neurologylive.com.
